















Alison Phillips, MPAP MHPE, PA-C, is a physician assistant working for the UNC Breast Cancer group with clusa Cargo. Clusa Cargo.
 Alison Philips, MPAP MHPE, PA-C, is a physician for the UNC Breast Cancer group with clusa Cargo.
 Boh as over rine years of clinical experience and an information for public breast and passing for the UNC Breast Cancer group with clinical deucation.
 Boh as over rine years of clinical experience and an approximation for public breast and information and provide the state of the UNC Breast Cancer group with clinical deucation.
 Boh as over rine years of clinical experience and an approximation of the UNC Breast Cancer group with the physical Assistant Plant and Improvide the assistant and Improvide the assist for public breast of provide the assist and improvide health literacy.

OIR PRESENTER



9





11

















Lor	arning Objectives
Lea	anning Objectives
1.	Recognize the common presentation, causes, and management of superior vena cava syndrome.
2.	Discuss the presentation, risk factors, and management of hypercalcemia in patients with cancer.
3.	Review the presentation, causes, and management of SIADH as it relates to patients undergoing cancer treatment.
8	
19	













 Extravasation 	
 Immunotherapy 	
 Hypersensitivity Reactions 	
5	







Causes of Hypercalcemia of Malignancy

• Excessive secretion of parathyroid hormone-related protein

• Release of osteoclasts from bone metastasis

• Excessive production of 1,25-dihydroxy Vitamin D (calcitriol)









Correcting for Hypoalbu	minemia	_
• Total serum calcium is serum calcium can be U low albumin	[°] 40% albumin bound, which means JNDER estimated in the patient with	_
• Corrected Calcium mg/ Patient's Albumin)+ Se	′dL = 0.8 x (Normal Albumin (4.0)- rum Calcium	_
8		_
34		











Prognosis of Hypercalcemia of Malignand	cy
 Even with treatment, approximately 50% presenting with hypercalcemia will die w 	6 of cancer patients vithin 30 days
 Believed to be related to this most often advanced stage cancer 	occurring in
 DOI: 10.1200]/GO.2016.006890 (surnal of Global Oncology 3 no. 6 (2017) 728-733. Published on 	line March 15, 2017.
8	











SIADHSyndrome of Inappropriate A	ntidiuretic Hormone		
ADH is usually released by the pituit high sodium levels	ary gland in response to	· 	
 Neuroendocrine tumor cells can cau too much antidiuretic hormone, cau fluid, leading to hyponatremia 	ise the body to secrete ising kidneys to retain		
 Certain cancer therapies, like plating methotrexate can also cause excess 	um chemotherapy and ive ADH secretion		
8			













Treatment of Acute SIADH (<48 hours onset)

- Water restriction
- 3% hypertonic saline
- Loop diuretics with hypertonic saline
- Vasopressin-2 receptor antagonists



49

8

 Fluid restriction 	
Vasopressin-2 rece	eptor antagonists
Consider loop diur mannitol, and den	etics with increased salt intake, urea, neclocycline
8	























59























